Penserra Capital Management LLC Buys 55,552 Shares of Hims & Hers Health, Inc. $HIMS

Penserra Capital Management LLC boosted its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 81.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 123,793 shares of the company’s stock after acquiring an additional 55,552 shares during the quarter. Penserra Capital Management LLC owned 0.05% of Hims & Hers Health worth $7,020,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Virtus Advisers LLC acquired a new stake in shares of Hims & Hers Health during the 2nd quarter worth about $26,000. Quent Capital LLC acquired a new stake in shares of Hims & Hers Health during the third quarter worth approximately $28,000. Quaker Wealth Management LLC bought a new position in shares of Hims & Hers Health in the second quarter valued at approximately $29,000. Geneos Wealth Management Inc. bought a new position in shares of Hims & Hers Health in the first quarter valued at approximately $30,000. Finally, Bessemer Group Inc. boosted its stake in Hims & Hers Health by 105.8% in the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after purchasing an additional 312 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Insider Buying and Selling

In other Hims & Hers Health news, insider Irene Becklund sold 8,411 shares of the stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $308,767.81. Following the sale, the insider directly owned 2,126 shares in the company, valued at approximately $78,045.46. This trade represents a 79.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Michael Chi sold 13,750 shares of the business’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $504,762.50. Following the completion of the transaction, the chief operating officer directly owned 305,161 shares of the company’s stock, valued at $11,202,460.31. This trade represents a 4.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 131,974 shares of company stock worth $4,763,800 over the last quarter. Insiders own 13.71% of the company’s stock.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims announced it will offer a compounded, oral semaglutide weight‑loss pill at an introductory price of $49 (then $99/mo), undercutting branded oral options and potentially capturing price‑sensitive patients and prescription volume. This move drove immediate market attention and earlier upside in HIMS shares. Read More.
• Positive Sentiment: Hims expanded its non‑prescription services by adding access to Galleri® multi‑cancer early detection testing, diversifying revenue beyond prescriptions and strengthening its digital health platform offering. Read More.
• Neutral Sentiment: The pill announcement generated broad media and analyst attention — boosting HIMS’ profile but also increasing scrutiny. Some analysts remain bullish on the company’s digital distribution model while others urge caution. Read More.
• Negative Sentiment: Novo Nordisk publicly accused Hims of illegal “mass compounding,” called the product unapproved and said it will take legal action — creating regulatory, litigation and advertising risk that could hit HIMS revenue and margins if challenged. Read More.
• Negative Sentiment: Major competitors (Novo Nordisk, Eli Lilly) criticized the offering and the move spurred volatility across the GLP‑1/oral weight‑loss market; sustained legal/regulatory pushback or adverse guidance could reverse any short‑term gains for HIMS. Read More.

Wall Street Analyst Weigh In

HIMS has been the topic of several research analyst reports. Leerink Partners upgraded Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, December 4th. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a research report on Monday, December 29th. Citigroup restated a “sell” rating on shares of Hims & Hers Health in a research report on Monday, January 5th. Wall Street Zen downgraded shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Finally, KeyCorp started coverage on shares of Hims & Hers Health in a research report on Tuesday, October 21st. They set a “sector weight” rating on the stock. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, nine have issued a Hold rating and four have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $42.62.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock opened at $23.50 on Friday. The firm has a fifty day moving average of $33.30 and a two-hundred day moving average of $43.64. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88. The stock has a market capitalization of $5.35 billion, a price-to-earnings ratio of 43.51, a PEG ratio of 4.02 and a beta of 2.43. Hims & Hers Health, Inc. has a 52 week low of $22.95 and a 52 week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 3rd. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The company had revenue of $598.98 million for the quarter, compared to analyst estimates of $578.99 million. During the same period last year, the firm earned $0.32 earnings per share. The firm’s revenue for the quarter was up 49.2% on a year-over-year basis. As a group, equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health declared that its board has initiated a share repurchase plan on Monday, November 17th that allows the company to repurchase $250.00 million in shares. This repurchase authorization allows the company to purchase up to 3% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s management believes its shares are undervalued.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.